PNPLA3 and metabolic dysfunction-associated steatotic liver disease: Evidence also suggests that PNPLA3 I148M may modify treatment response, with an effect on body weight and liver fat reduction in NAFLD patients (Carlsson et al., 2020) (i.e., lifestyle modification, bariatric surgery, omega-3 fatty acids).